Atreca Inc.

12.29-0.4200-3.30%Vol 404.86K1Y Perf -20.88%
Apr 9th, 2021 16:00 DELAYED
BID12.01 ASK12.60
Open12.57 Previous Close12.71
Pre-Market- After-Market-
 - -  - -%
Target Price
29.00 
Analyst Rating
Strong Buy 1.00
Potential %
135.96 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap452.65M 
Earnings Rating
Price Range Ratio 52W %
0.70 
Earnings Date
13th May 2021

Today's Price Range

12.2012.73

52W Range

12.2025.03

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-10.23%
1 Month
-31.91%
3 Months
-19.62%
6 Months
-17.85%
1 Year
-20.88%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCEL12.29-0.4200-3.30
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.63-0.630.00
Q03 2020-0.60-0.66-10.00
Q02 2020-0.77-0.717.79
Q01 2020-0.74-0.731.35
Q04 2019-0.64-0.72-12.50
Q03 2019-0.73-0.5721.92
Q02 2019-0.96-3.67-282.29
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date13th May 2021
Estimated EPS Next Report-0.65
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume404.86K
Shares Outstanding36.83M
Trades Count4.93K
Dollar Volume5.64M
Avg. Volume259.45K
Avg. Weekly Volume297.30K
Avg. Monthly Volume309.79K
Avg. Quarterly Volume269.11K

Atreca Inc. (NASDAQ: BCEL) stock closed at 12.29 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 404.88K shares and market capitalization of 452.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Atreca Inc. CEO is John A. Orwin.

The one-year performance of Atreca Inc. stock is -20.88%, while year-to-date (YTD) performance is -23.9%. BCEL stock has a five-year performance of %. Its 52-week range is between 12.2 and 25.03, which gives BCEL stock a 52-week price range ratio of 0.70%

Atreca Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 2.34, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.59%, a ROC of -36.63% and a ROE of -38.75%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Atreca Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Atreca Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Atreca Inc. is Strong Buy (1), with a target price of $29, which is +135.96% compared to the current price. The earnings rating for Atreca Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atreca Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atreca Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.17, ATR14 : 1.41, CCI20 : -68.17, Chaikin Money Flow : -0.10, MACD : 0.38, Money Flow Index : 40.90, ROC : 0.85, RSI : 52.85, STOCH (14,3) : 41.58, STOCH RSI : 0.46, UO : 49.65, Williams %R : -58.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atreca Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (100.00 %)
9 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Atreca Inc.

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

CEO: John A. Orwin

Telephone: +1 650 595-2595

Address: 450 East Jamie Court, South San Francisco 94080, CA, US

Number of employees: 128

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

News

Stocktwits